Earnings Update: Inari Medical, Inc. (NASDAQ:NARI) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
Earnings Update: Inari Medical, Inc. (NASDAQ:NARI) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
There's been a notable change in appetite for Inari Medical, Inc. (NASDAQ:NARI) shares in the week since its second-quarter report, with the stock down 16% to US$46.56. Revenues were in line with expectations, at US$146m, while statutory losses ballooned to US$0.54 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
自Inari Medical公司(NASDAQ:NARI)在二季報告發布以來的一週內,其股票下跌16%至46.56美元后,其股票的興趣出現了明顯變化。營業收入符合預期,爲1.46億美元,而法定虧損則膨脹至每股0.54美元。分析師通常會在每次盈利報告後更新他們的預測,我們可以從他們的估計中判斷他們對公司的看法是否發生了變化或者是否存在任何值得注意的新問題。我們已收集了最新的法定預測,以查看分析師是否在這些結果之後改變了盈利模型。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240801/0-4710dd169861973305dde80f7c5757cc-0-bdeb017b604d9f0ed777753096d63630.png/big)
Following the latest results, Inari Medical's eleven analysts are now forecasting revenues of US$599.6m in 2024. This would be a decent 9.5% improvement in revenue compared to the last 12 months. Losses are forecast to narrow 2.5% to US$0.95 per share. Before this earnings announcement, the analysts had been modelling revenues of US$598.7m and losses of US$0.91 per share in 2024. So it's pretty clear consensus is mixed on Inari Medical after the new consensus numbers; while the analysts held their revenue numbers steady, they also administered a moderate increase in per-share loss expectations.
在最新結果公佈後,Inari Medical的11位分析師現在預測,2024年收入將達到5.996億美元,這將是過去12個月中收入相比的不錯的9.5%增長。預計虧損將縮小2.5%至每股0.95美元。在此盈利公告之前,分析師已經對2024年預測收入爲5.987億美元和每股虧損爲0.91美元。所以顯然,在新的共識數字之後,人們對Inari Medical的共識是融合的。儘管分析師保持他們的收入數就業穩定,但他們還推行了每股虧損預期的適度增加。
As a result, there was no major change to the consensus price target of US$66.40, with the analysts implicitly confirming that the business looks to be performing in line with expectations, despite higher forecast losses. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Inari Medical at US$86.00 per share, while the most bearish prices it at US$50.00. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.
因此,共識價值目標沒有發生重大變化,仍然是66.40美元,分析師隱含確認,儘管預期虧損增加,但該企業的表現符合預期。共識價格目標僅是各個分析師目標的平均值,因此看一下基礎估計範圍有多廣泛可能很有用。目前,最看好的分析師將Inari Medical的價值定在每股86.00美元,而看空的分析師將其定價爲每股50.00美元。這些價格目標表明分析師對企業的看法存在一些差異,但是估計值的差異不足以使我們認爲一些人正在押注野心勃勃的成功或徹底的失敗。
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's pretty clear that there is an expectation that Inari Medical's revenue growth will slow down substantially, with revenues to the end of 2024 expected to display 20% growth on an annualised basis. This is compared to a historical growth rate of 29% over the past three years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 8.2% per year. So it's pretty clear that, while Inari Medical's revenue growth is expected to slow, it's still expected to grow faster than the industry itself.
獲得有關這些預測的更多背景信息的一種方法是查看它們與過去的業績以及同行業其他公司表現的比較。很明顯,人們期望Inari Medical的收入增長大大減緩,到2024年底預計的年增長率爲20%。相比之下,過去三年的歷史增長率爲29%。將此與行業中分析師涵蓋的其他公司進行比較,這些公司預計年均增長8.2%。因此,顯然,儘管預計Inari Medical的收入增長將放緩,但其仍有望比行業本身增長更快。
The Bottom Line
最重要的事情是分析師增加了它對下一年每股虧損的估計。令人欣慰的是,營收預測未發生重大變化,業務仍有望比整個行業增長更快。共識價格目標穩定在28.50美元,最新估計不足以對價格目標產生影響。
The most important thing to take away is that the analysts increased their loss per share estimates for next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
最重要的是,分析師增加了明年每股虧損的預測。幸運的是,他們還重新確認了收入數字,表明它正在按預期進行跟蹤。此外,我們的數據表明,收入預計將比更廣泛的行業增長更快。共識價格目標沒有真正改變,這表明企業的內在價值沒有隨着最新估計發生任何重大變化。
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Inari Medical analysts - going out to 2026, and you can see them free on our platform here.
請記住,我們認爲考慮更長期的業務軌跡對投資者來說更爲重要。我們有多個Inari Medical分析師的估計,其可達到2026年,您可以在此處免費查看它們。
You can also see our analysis of Inari Medical's Board and CEO remuneration and experience, and whether company insiders have been buying stock.
您還可以看到我們對Inari Medical的董事會和首席執行官薪酬以及經驗的分析,以及公司內部人員是否一直在購買股票。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。